A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

NCT07023731 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

159

Enrollment

INDUSTRY

Sponsor class

Conditions

KRAS G12D Mutation
Advanced Solid Cancer

Interventions

DRUG: ARV-806

Sponsor

Arvinas Inc.